KBP Biosciences (Biotechnology, Health Care) — Funding, Investors & Signals 2026

KBP Biosciences

At KBP we are consistently reminded that patient care is the end goal of what we do daily.

Founded 2007

Princeton, United States 40 employees Series A Total: $76.00M Biotechnology, Health Care +1

KBP Biosciences is a biotechnology startup founded in 2007 and headquartered in the United States. The company's slogan "At KBP we are consistently reminded that patient care is the end goal of what we do daily" reflects its unwavering dedication to improving patient outcomes. KBP boasts a highly experienced discovery team that focuses on identifying new compounds with potential, resulting in a deep pipeline of clinical and pre-clinical compounds. Their research is laser-focused on three primary organ systems – lung, heart, and kidney – and is capable of assessing a drug’s activity and active mechanism in both in vitro and in vivo models. Moreover, KBP has an antimicrobial group leveraging a proprietary microbial bank comprised of 20,000+ clinically-isolated strains, allowing them to effectively evaluate internally generated drug candidates. The company's immunology group conducts research on the roles of T- and B-cells in various diseases, providing powerful and unique insights that open up new avenues to tackle specific targets. In January 2018, KBP Biosciences secured a significant $76.00M Series A investment from a consortium of investors including Cowin Capital, EFung Capital, Bay City Capital, Ping An Ventures, AdvanTech Capital, Korean Investment Partners, SDIC Ventures, Elite Capital, Sangel Capital, and CASH Capital. This substantial investment is a testament to the confidence that these prominent investors have in KBP's innovative approach to developing therapies for a wide variety of illnesses.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	••••••	10	•••• ••••	05 Jan 2018

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

••••••

•••• ••••

05 Jan 2018

FAQ About KBP Biosciences

At KBP we are consistently reminded that patient care is the end goal of what we do daily.

KBP Biosciences was founded in 2007.

KBP Biosciences is headquartered in Princeton, United States.

KBP Biosciences operates in the following industries: Biotechnology, Health Care, Pharmaceutical.

KBP Biosciences has approximately 40 employees.

KBP Biosciences has completed 1 funding round, raising a total of $76.00M. The latest funding stage is Series A.

Top alternatives and competitors to KBP Biosciences include Emulate, Inc., Ceramedix, Inc., Barcelona Liver Bioservices, AltPep, Finnadvance. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

KBP Biosciences and Emulate, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

KBP Biosciences

General Information

Track KBP Biosciences

Discover More

About KBP Biosciences

Funding Rounds & Investors (1)

KBP Biosciences Alternatives & Competitors

FAQ About KBP Biosciences

Don't just browse. Track.